lifibrol has been researched along with Hyperlipoproteinemia Type II in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Friedrich, I; Gierens, H; Klima, B; Köster, W; März, W; Nuber, C; Schaefer, JR; Scharnagl, H; Soufi, M; Wieland, H; Winkler, K | 1 |
1 trial(s) available for lifibrol and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia.
Topics: Adult; Apolipoprotein A-I; Butanols; Cholesterol, HDL; Humans; Hydroxybenzoates; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged | 2000 |